Mouse Anti-EGFR Recombinant Antibody (clone mAb528) (CAT#: PABZ-039)

Figure 1 Cell-surface EGFRs were measured by FACS with flow cytometry.

The cells were collected for FACS analysis of the distribution of FITC-positive cells. The data are plotted for cell numbers versus the intensity of fluorescence. Total numbers of cells counted in each cell line (stained respectively with a control IgG and the anti-EGFR mAb 528) are shown at the top.

Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., ... & Fan, Z. (2007). Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer research, 67(17), 8240-8247.

Figure 2 Inhibition of EGF receptor (EGFR) activation by the ipsilateral immunoblocking with monoclonal antibody MAb528.

Monolayers were treated apically (A) and basolaterally (B) with either vehicle, 1 nM EGF alone, and 50 nM EGF alone, or with 20 nM (1:25 dilution) MAb528 (added 30 min before EGF). TER was monitored with an EVOM at indicated times after EGF treatment. Data are means ± SE of 3 replicate wells and are representative of experiments from 4 separate cell preparations.

Chen, M. C., Goliger, J., Bunnett, N., & Soll, A. H. (2001). Apical and basolateral EGF receptors regulate gastric mucosal paracellular permeability. American Journal of Physiology-Gastrointestinal and Liver Physiology, 280(2), G264-G272.